quadraScope invests in healthcare companies developing pharmaceuticals, diagnostics, software, equipment and devices enabling disease treatment and prevention through biological age reversal.
Hallmarks of aging
Biogerontology is the new science that aims to extend human healthspan by addressing the biological basis of aging. It revolves around the concept of the Hallmarks of Aging, a framework introduced in 2013 by López-Otín et al. and further expanded in the paper Hallmarks of Aging: An Expanding Universe in 2023. The hallmarks of aging are shown below.
Genomic instability
Accumulation of DNA mutations due to failure of DNA repair mechanisms.
Telomere attrition
Shortening of the protective caps at the ends of chromosomes, leading to DNA damage and senescence.
Epigenetic alterations
Modifications in the way DNA is stored, read, and expressed, without altering the gene sequence.
Cellular senescence
Senescent cells are no loner able to divide, cannot die, and contribute to inflammation.
Mitochondrial dysfunction
Mitochondria, the energy-producing structures within cells, become leaky and inefficient.
Stem cell exhaustion
A decline in the number and function of stem cells, which are responsible for maintaining and repairing tissues.
Deregulated nutrient-sensing
Disruption of the mechanisms that control metabolism, utilization of nutrients, and energy balance.
Loss of proteostasis
Failure to maintain protein quality and function, leading to the accumulation of damaged proteins.
Disabled macroautophagy
Decreased ability to break down and recycle damaged or unnecessary cellular parts.
Altered intercellular communication
Communication systems between cells become unstable and cells lose the ability to work together effectively.
Chronic inflammation
The immune system stays persistently active even when there is no infection to fight or injury to repair.
Dysbiosis
Unbalanced populations of microorganisms that live in the human body.
Portfolio
Learn more
Learn more
Learn more
Learn more
Learn more
Learn more
Mechanism of action-based therapies for aging, with a focus on the role of lipids in metabolic diseaseLearn more
Aubrey de Grey, PhD
President & CSO, Longevity Escape Velocity Foundation
Team
We are a women-led team with a strong track record of taking new ventures from inception to profitable exits, including a 12x exit, and deep understanding of the emerging longevity science and market.
Core team
Scientific advisory board
Business advisory board
The quadraScope team is focused on the right sector, with the right team to select and vet investment opportunities. The rejuvenation industry is an emerging next wave of biotech technologies that has seen a recent surge in funding while engaging the top scientific talent.
Hans Keirstead, PhD
Chairman, Immunis
We chose to partner with quadraScope because of the strategic alignment of our visions, namely the importance of investment in programs that extend life-span and health-span while at the same time applying the same science to treat diseases that have no treatment.
Menachem Abraham
Co-founder & CEO, Klogenix
quadraScope is tapping the fast-emerging rejuvenation market with an abundance of research ready to be commercialized. With their strategic locations in Boston and Tel-Aviv they are poised to leverage the high concentration of biotech academia, industry and talent pool.
Reason
CEO, Repair Biotechnologies
I am privileged to serve on quadraScope’s scientific advisory board. I do so because Fiona and her colleagues have made, and continue to make, outstanding choices of investments in the longevity space. quadraScope’s portfolio consists of a wisely diversified set of companies at a variety of stages of preclinical and clinical development, each possessing unique and immensely exciting technology that promises to contribute substantially to medical progress.
Aubrey de Grey, PhD
President & CSO, Longevity Escape Velocity Foundation
quadraScope, our first investor, has encouraged the formation of rejuvenation clinics and has been active in defining the treatment protocols as a strategic pillar alongside clinical trials.